Panacea Biotec Limited (PANACEABIO) fundamentals
Panacea Biotec Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as PANACEABIO (ISIN INE922B01023). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Panacea Biotec Limited does
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.
Valuation and market data
| Last close | ₹399.90 |
|---|---|
| Market capitalisation | ₹2,545 crore |
| Enterprise value | ₹2,555 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.06 |
| Price to sales (TTM) | 3.70 |
| Book value per share | ₹130.50 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Apr 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹431 crore | ₹-44 crore | ₹-30 crore | 0.00 |
| Mar 2025 | ₹326 crore | ₹-26 crore | ₹-15 crore | -2.49 |
| Mar 2024 | ₹385 crore | ₹4 crore | ₹4 crore | 0.58 |
| Mar 2023 | ₹292 crore | ₹-63 crore | ₹-88 crore | -14.29 |
| Mar 2022 | ₹248 crore | ₹-94 crore | ₹-94 crore | -15.28 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 72.5% |
|---|---|
| Foreign institutions (FII) | 2.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.3% |
| Retail and others | 23.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.